HLA class I and II genotype in uveal melanoma: Relation to occurrence and prognosis

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 1, 2006, Pages 3-6

  Maat, Willem ^a   Haasnoot, Geert W ^a   Claas, Frans H J ^a   Schalij Delfos, Nicoline E ^a   Schreuder, Geziena M T ^a   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B35 ANTIGEN; HLA B44 ANTIGEN; HLA B60 ANTIGEN; HLA DR13 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CILIARY BODY; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA DETERMINATION; ENUCLEATION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SPINDLE CELL; TUMOR LOCALIZATION; TUMOR VOLUME; UVEA MELANOMA; AGED; BRACHYTHERAPY; GENETIC PREDISPOSITION; GENETICS; HISTOCOMPATIBILITY TEST; HYPERTHERMIC THERAPY; MELANOMA; MIDDLE AGED; MORTALITY; SURVIVAL RATE; UVEA TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CYTOTOXICITY TESTS, IMMUNOLOGIC; EYE ENUCLEATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; HUMANS; HYPERTHERMIA, INDUCED; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; UVEAL NEOPLASMS;

EID: 33644837847     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1122     Document Type: Article

References (24)

1. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995;16:487-494.
2. Gumperz JE, Parham P. The enigma of the natural killer cell. Nature. 1995;378:245-248.
3. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res. 1995;67:155-195.
4. Blom DJ, Luyten GP, Mooy C, et al. Human leukocyte antigen class I expression: marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997;38:1865-1872.
5. Ericsson C, Seregard S, Bartolazzi A, et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:2153-2156.
6. Jager MJ, Hurks HM, Levitskaya J, Kiessling R. HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol. 2002;63:444-451.
7. Lopez-Larrea C, Gonzalez S, Martinez-Borra J. The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy. Mol Med Today. 1998;4:540 -549.
8. Dieckhues B, Junemann G, Kuchle HJ, Puttmann T. [HLA-antigens in eye diseases (author's transl).] Klin Monatsbl Augenheilkd. 1979;175:681-685.
9. Pollack MS, Livingston PO. HLA and DR antigen frequencies in melanoma patients: possible relation to disease and prognosis. Tissue Antigens. 1985;26:262-265.
10. Lee JE, Abdalla J, Porter GA, et al. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002;9:587-593.
11. Ignatov RK, Terent'eva LS, Shul'gina NS. [Distribution of the HLA antigen system in melanoblastoma of the uvea.] Oftalmol Zh. 1977;32:289-294.
12. Volker-Dieben HJ, D'Amaro J, de Lange P, Rouendaal DW. HLA and ABO antigens in malignant choroidal melanoma. Clin Exp Immunol. 1983;53:581-588.
13. Bertrams J, Spitznas M, Rommelfanger M. Missing evidence for HLA antigen association with Eales' disease, chorioretinitis, central serous retinopathy, and malignant choroidal melanoma. Invest Ophthalmol Vis Sci. 1978;17:918-920.
14. Martinetti M, Tafi A, De Paoli F, Dugoujon JM, Belvedere MC. Immunogenetic heterogeneity of uveal melanoma. Cancer Detect Prev. 1988;12:145-148.
15. Jager MJ, Volker-Dieben HJ, Wolff-Rouendaal D, Kakebeeke-Kemme H, D'Amaro J. Possible relation between HLA and ABO type and prognosis of uveal melanoma. Doc Ophthalmol. 1992; 82:43-47.
16. Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M. HLA gene and haplotype frequencies in Dutch blood donors. Tissue Antigens. 1996;48:562-574.
17. Terasaki PI, McClelland JD. Microdroplet assay of human serumcytotoxins. Nature. 1964;204:998-1000.
18. Naipal AM, D'Amaro J, Bruning JW, van Leeuwen A, van Rood JJ. Automated reading of propidium iodide lymphocytotoxicity tests for HLA-DR, MB, MT typing. Tissue Antigens. 1984;24:302-306.
19. Verduyn W, Doxiadis II, Anholts J, et al. Biotinylated DRB sequence-specific oligonucleotides: comparison to serologic HLA-DR typing of organ donors in eurotransplant. Hum Immunol. 1993; 37:59-67.
20. Haldane JB. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet. 1956;20:309-311.
21. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251-253.
22. Edwards JH. HLA and disease: the detection of associations. J Immunogenet. 2005;1974:249.
23. The Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma: COMS report no. 4. Arch Ophthalmol. 1997;115:886-893.
24. Gaudieri S, Nolan D, McKinnon E, et al. Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses. Mol Immunol. 2005;42:557-560.